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Complex and widespread with about 90% of the global
burden in sub-Saharan Africa, malaria remains a signifi-
cant health problem. Malaria vaccines have the chance to
make significant inroads, with RTS,S vaccine candidate as
the most advanced candidate. However, the need for a
highly efficacious, long-lasting vaccine is still unmet. Con-
tinued support for a repertoire of tools for Plasmodium
falciparum is needed. A blood-stage vaccine is desirable to
deal with morbidity and mortality secondary to P. falci-
parum infection, and thus would be a valuable strategy in
the fight against malaria.
The P. falciparum serine repeat antigen-5 formulated
with aluminum hydroxyl gel (BK-SE36) is a blood-stage
malaria vaccine candidate. The processing of SERA5 is
believed to mediate parasite egress from the infected red
blood cell. Field studies show good correlations of anti-
SERA antibodies to malaria protection against blood para-
sitemia, malaria symptoms and severe disease. A Phase 1a
trial demonstrated its safety and immunogenicity in
malaria naïve Japanese adults. A Phase 1b trial was con-
ducted in the malaria endemic area of Northern Uganda
to assess the vaccine’s safety and immunogenicity. BK-
SE36 had an acceptable safety and immunogenicity profile.
Post-trial, Stage 2 subjects were age-matched to 50 control
individuals to compare malaria episodes 130–365 days
post-second vaccination. Log-rank test reveal significant
differences in BK-SE36 vaccinees vs control group in
time-to-first episodes with parasitemias ≥5,000/μL and
those with ≥5,000/μL + fever (protective efficacy for the
latter is 72%, P < 0.01). BK-SE36 vaccinees have fewer
multiple malaria episodes with high parasitemia. We also
observed that the antibody titers against SE36 were
boosted after episodes of natural infection. Above results
show that BK-SE36 could provide some protection against
natural P. falciparum infection until 1 year post-second
vaccination.
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